Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
With the modality now in early clinical trials, experts say more efficiency, broader editing capabilities and delivery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback